Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Authors: Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Chen A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Gutierrez M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Pfister TD; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wang L; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Redon C; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bonner WM; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yutzy W; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zhang Y; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Ji J; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Allen D; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Eiseman JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Holleran JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Rubinstein L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Collins J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Tomaszewski J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA., Parchment R; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Pommier Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Room 3A44, Bethesda, MD, 20814, USA. doroshoj@mail.nih.gov.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. doroshoj@mail.nih.gov.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Jul; Vol. 78 (1), pp. 73-81. Date of Electronic Publication: 2016 May 11.
Publication Type: Comparative Study; Controlled Clinical Trial; Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0843
DOI:10.1007/s00280-016-2998-6